# OnCo record pirtobrutinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/pirtobrutinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "pirtobrutinib" ;
  schema:name "Pirtobrutinib"@en ;
  schema:description "A BTK blocker that works after the older ones stop, because it grips a different part of the enzyme. Fully approved for CLL in December 2025."@en ;
  schema:url <https://onco.cc/drugs/pirtobrutinib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Pirtobrutinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q116622551> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Pirtobrutinib>, <https://doi.org/10.1056/NEJMoa1400029>, <https://doi.org/10.1056/NEJMoa2300696>, <https://doi.org/10.1182/bloodadvances.2022008325> ;
  onco:status "approved" ;
  onco:modality "Small-molecule non-covalent (reversible) BTK inhibitor" ;
  schema:alternateName "Jaypirca" ;
  onco:approval "US 2023: Relapsed MCL after BTK inhibitor (accelerated, January); CLL/SLL after BTK and BCL-2 inhibitors (accelerated, December)", "US 2025: Relapsed/refractory CLL/SLL after a covalent BTK inhibitor (traditional approval, BRUIN CLL-321)" ;
  onco:acceleratedApproval "US 2023-01-27: Adult patients with relapsed or refractory mantle cel lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.", "US 2023-12-01: Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor" ;
  onco:acceleratedApprovalConfirmed "US 2025-12-02: Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor" ;
  onco:cancers <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/cll-relapsed/>, <https://onco.cc/cancers/richter-transformation-cll/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/btk/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/> ;
  onco:terms <https://onco.cc/terms/richter-transformation/> ;
  onco:trials <https://onco.cc/trials/bruin-cll-321/>, <https://onco.cc/trials/nct07162181/>, <https://onco.cc/trials/nct06973187/>, <https://onco.cc/trials/nct06588478/>, <https://onco.cc/trials/nct05023980/>, <https://onco.cc/trials/nct05254743/>, <https://onco.cc/trials/nct04965493/>, <https://onco.cc/trials/nct04662255/> .